The Diabetes Prevention Program Outcomes Study AD/ADRD Project

NCT05704309 · tracked via the Priya Life Science Mexico tracker

Sponsor

Marinella Temprosa

Phase

Observational

Started

2022-11-07

Last updated

2025-08-26

Condition(s) studied

DiabetesAlzheimer DiseaseDementia, VascularDementiaPreDiabetes

Study summary

The DPPOS AD/ADRD project will address the overarching question: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes (PreD) and type 2 diabetes (T2D), who are a high-risk group for cognitive impairment and represent a large fraction of the United States (US) population? This U19 proposal addresses the National Alzheimer's Project Act goal to "prevent, halt, or reverse AD" in the high-risk group of persons with pre-diabetes and type 2 diabetes, who represent over half of the population aged 60 years and older in the US.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: * All surviving participants originally randomized in the Diabetes Prevention Program * For Brain Imaging subcohort, only participants aged 55 years and older and those without contraindication to MRI will be included. Contraindications to MRI include the inability to lie flat, claustrophobia, and the presence of indwelling metallic objects, medical or non-medical, that are not 3T MRI compatible. Exclusion Criteria: \-

Primary outcome measure(s)

Cognitive Diagnoses — Sept 2022 to October 2026
Classification of normal, mild cognitive impairment or dementia based on NACC UDS

Trial sites (27)

Facility	City	Region
SW American Indian Center - Phoenix	Phoenix	Arizona
University of California Los Angeles	Alhambra	California
University of California San Diego	San Diego	California
University of Colorado	Aurora	Colorado
Medstar Health Research Institute	Washington D.C.	District of Columbia
University of Miami	Miami	Florida
University of Hawaii	Honolulu	Hawaii
Northwestern University	Chicago	Illinois
University of Chicago	Chicago	Illinois
Indiana University	Indianapolis	Indiana
Pennington Biomedical Center	Baton Rouge	Louisiana
Johns Hopkins University	Lutherville	Maryland
Biostatistics Center, George Washington University	Rockville	Maryland
Massachusetts General Hospital	Boston	Massachusetts
Joslin Diabetes Center	Boston	Massachusetts
Washington University	St Louis	Missouri
University of New Mexico	Albuquerque	New Mexico
SW American Indian Center - Shiprock	Shiprock	New Mexico
SW American Indian Center - Zuni	Zuni	New Mexico
Columbia University Medical Center	New York	New York
Columbia University	New York	New York
Albert Einstein College of Medicine	The Bronx	New York
Thomas Jefferson University	Philadelphia	Pennsylvania
University of Pittsburgh	Pittsburgh	Pennsylvania
University of Tennessee	Memphis	Tennessee
University of Texas Health Science Center San Antonio	San Antonio	Texas
University of Washington, VA Puget Sound Health Care System	Seattle	Washington

Other trials for the same condition

Proteinopathies Expression in Skin of Neurodegenerative Disorders Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) Active, not recruiting

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) Recruiting

Multidisciplinary Care for Lifestyle Change for Metabolic Control and Quality of Life in Prediabetes (PreCPro) Recruiting

Biomarkers for Vascular Contributions to Cognitive Impairment and Dementia Consortium Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05704309 on ClinicalTrials.gov ↗ ← All trials in Mexico